Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis.

Keaney TC, Bhutani T, Sivanesan P, Bandow GD, Weinstein SB, Cheung LC, Malick F, Koo J.

J Am Acad Dermatol. 2012 Oct;67(4):636-41. doi: 10.1016/j.jaad.2011.10.033. Epub 2012 Jan 4.

PMID:
22221776
2.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.

Kubota Y, Yoneda K, Nakai K, Katsuura J, Moriue T, Matsuoka Y, Miyamoto I, Ohya Y.

J Am Acad Dermatol. 2009 Feb;60(2):212-7. doi: 10.1016/j.jaad.2008.09.034. Epub 2008 Nov 22.

PMID:
19027990
3.

Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.

Singalavanija S, Noppakun N, Limpongsanuruk W, Wisuthsarewong W, Aunhachoke K, Chunharas A, Wananukul S, Akaraphanth R.

J Med Assoc Thai. 2006 Nov;89(11):1915-22.

PMID:
17205874
4.

A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea.

Won CH, Seo PG, Park YM, Yang JM, Lee KH, Sung KJ, Park CW, Kim DW, Chang HS, Won YH, Kim KH.

J Dermatolog Treat. 2004 Jan;15(1):30-4.

PMID:
14754647
5.

A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.

Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M.

J Dtsch Dermatol Ges. 2008 Jul;6(7):548-53. doi: 10.1111/j.1610-0387.2008.06641.x. Epub 2008 Jan 30. English, German.

PMID:
18248495
6.

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group.

Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M.

Arch Dermatol. 2000 Aug;136(8):999-1006.

PMID:
10926735
7.

Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study.

Braza TJ, DiCarlo JB, Soon SL, McCall CO.

Br J Dermatol. 2003 Jun;148(6):1242-4.

PMID:
12828755
8.

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.

Hultsch T, Kapp A, Spergel J.

Dermatology. 2005;211(2):174-87. Review. Erratum in: Dermatology. 2005;211(3):292.

9.

Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.

Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E; US Tacrolimus Ointment Study Group.

Pediatrics. 2005 Sep;116(3):e334-42.

PMID:
16140675
10.

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.

Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C; European Tacrolimus Ointment Study Group.

Br J Dermatol. 2005 Jun;152(6):1282-9.

PMID:
15948994
11.

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.

Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, van der Valk PG, Sharpe G, Smith CH, Dobozy A, Turjanmaa K; European Tacrolimus Ointment Study Group.

Acta Derm Venereol. 2007;87(1):54-61.

12.

Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.

Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, Ortonne JP.

Br J Dermatol. 2009 Aug;161(2):427-34. doi: 10.1111/j.1365-2133.2009.09143.x. Epub 2009 Apr 16.

PMID:
19416227
13.

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.

Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R; European Tacrolimus Ointment Group.

Br J Dermatol. 2004 Mar;150(3):554-62.

PMID:
15030341
14.

Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, Marks I, Cherill R, Emady-Azar S, Paul C; Multicentre Investigator Group.

Br J Dermatol. 2005 Jun;152(6):1296-303.

PMID:
15948996
15.

Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis.

Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, Arcangeli F.

Allergy. 2007 Feb;62(2):184-9.

16.

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.

Chen SL, Yan J, Wang FS.

J Dermatolog Treat. 2010 May;21(3):144-56. doi: 10.3109/09546630903401470. Review.

PMID:
20394490
17.
18.

Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.

Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y.

Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 1):321-9. doi: 10.1111/j.1399-3038.2009.00895.x. Epub 2009 Jun 26.

PMID:
19563466
19.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group.

Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM.

J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):637-44.

PMID:
9802373
20.

Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.

Leung DY, Hanifin JM, Pariser DM, Barber KA, Langley RG, Schlievert PM, Abrams B, Hultsch T.

Br J Dermatol. 2009 Aug;161(2):435-43. doi: 10.1111/j.1365-2133.2009.09145.x. Epub 2009 Mar 30.

PMID:
19416245

Supplemental Content

Support Center